<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04383743</url>
  </required_header>
  <id_info>
    <org_study_id>RG1006206</org_study_id>
    <secondary_id>NCI-2019-08028</secondary_id>
    <secondary_id>10439</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT04383743</nct_id>
  </id_info>
  <brief_title>Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer</brief_title>
  <official_title>Pembrolizumab and aMVAC Chemotherapy as Neoadjuvant Therapy in Non-Urothelial Histology Muscle-Invasive Bladder Cancer: A Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study is evaluating how well pembrolizumab and combination chemotherapy before&#xD;
      surgery work for the treatment of specific types of muscle-invasive bladder cancer that have&#xD;
      unusual appearance (variants). Immunotherapy with monoclonal antibodies, such as&#xD;
      pembrolizumab, may help the body's immune system attack the cancer, and may interfere with&#xD;
      the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as&#xD;
      methotrexate, vinblastine, adriamycin, and cisplatin work in different ways to stop the&#xD;
      growth of tumor cells, either by killing the cells, by stopping them from dividing, or by&#xD;
      stopping them from spreading. Giving pembrolizumab and combination chemotherapy before&#xD;
      surgery may work better in treating patients with these muscle invasive bladder cancer&#xD;
      variants compared to chemotherapy alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE:&#xD;
&#xD;
      Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1 of weeks 0, 3, and&#xD;
      6 and methotrexate IV, vinblastine IV, doxorubicin IV, and cisplatin IV on day 1 of weeks 0,&#xD;
      2, 4, and 6 in the absence of disease progression or unacceptable toxicity. Patients also&#xD;
      receive pegfilgrastim subcutaneously (SC) on day 1 or 2 of weeks 0, 2, 4, and 6 in the&#xD;
      absence of disease progression or unacceptable toxicity. Patients then undergo standard of&#xD;
      care radical cystectomy.&#xD;
&#xD;
      After completion of study treatment, patients are followed up about 1 month after surgery and&#xD;
      then every 3-6 months for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 24, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic complete response rate</measure>
    <time_frame>At time of radical cystectomy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 90 days post treatment</time_frame>
    <description>Will evaluate the frequency and severity of toxicity of the regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor infiltrating lymphocyte (TIL) density</measure>
    <time_frame>At time of radical cystectomy</time_frame>
    <description>TIL density will be summarized by means, medians, and quantiles. Changes will be evaluated as both absolute and percentage change. Descriptive statistics will also be used when needed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>At 2 years</time_frame>
    <description>Will be estimated using the method of Kaplan-Meier.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">17</enrollment>
  <condition>Stage II Bladder Cancer AJCC v8</condition>
  <condition>Stage IIIA Bladder Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Treatment (pembrolizumab, aMVAC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive pembrolizumab IV over 30 minutes on day 1 of weeks 0, 3, and 6 and methotrexate IV, vinblastine IV, doxorubicin IV, and cisplatin IV on day 1 of weeks 0, 2, 4, and 6 in the absence of disease progression or unacceptable toxicity. Patients also receive pegfilgrastim SC on day 1 or 2 of weeks 0, 2, 4, and 6 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care radical cystectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (pembrolizumab, aMVAC)</arm_group_label>
    <other_name>Abiplatin</other_name>
    <other_name>Blastolem</other_name>
    <other_name>Briplatin</other_name>
    <other_name>CDDP</other_name>
    <other_name>Cis-diammine-dichloroplatinum</other_name>
    <other_name>Cis-diamminedichloridoplatinum</other_name>
    <other_name>Cis-diamminedichloro Platinum (II)</other_name>
    <other_name>Cis-diamminedichloroplatinum</other_name>
    <other_name>Cis-dichloroammine Platinum (II)</other_name>
    <other_name>Cis-platinous Diamine Dichloride</other_name>
    <other_name>Cis-platinum</other_name>
    <other_name>Cis-platinum II</other_name>
    <other_name>Cis-platinum II Diamine Dichloride</other_name>
    <other_name>Cismaplat</other_name>
    <other_name>Cisplatina</other_name>
    <other_name>Cisplatinum</other_name>
    <other_name>Cisplatyl</other_name>
    <other_name>Citoplatino</other_name>
    <other_name>Citosin</other_name>
    <other_name>Cysplatyna</other_name>
    <other_name>DDP</other_name>
    <other_name>Lederplatin</other_name>
    <other_name>Metaplatin</other_name>
    <other_name>Neoplatin</other_name>
    <other_name>Peyrone''s Chloride</other_name>
    <other_name>Peyrone''s Salt</other_name>
    <other_name>Placis</other_name>
    <other_name>Plastistil</other_name>
    <other_name>Platamine</other_name>
    <other_name>Platiblastin</other_name>
    <other_name>Platiblastin-S</other_name>
    <other_name>Platinex</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol- AQ</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol-AQ VHA Plus</other_name>
    <other_name>Platinoxan</other_name>
    <other_name>Platinum</other_name>
    <other_name>Platinum Diamminodichloride</other_name>
    <other_name>Platiran</other_name>
    <other_name>Platistin</other_name>
    <other_name>Platosin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (pembrolizumab, aMVAC)</arm_group_label>
    <other_name>Adriablastin</other_name>
    <other_name>Hydroxydaunomycin</other_name>
    <other_name>Hydroxyl Daunorubicin</other_name>
    <other_name>Hydroxyldaunorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (pembrolizumab, aMVAC)</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>Alpha-Methopterin</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Brimexate</other_name>
    <other_name>CL 14377</other_name>
    <other_name>CL-14377</other_name>
    <other_name>Emtexate</other_name>
    <other_name>Emthexat</other_name>
    <other_name>Emthexate</other_name>
    <other_name>Farmitrexat</other_name>
    <other_name>Fauldexato</other_name>
    <other_name>Folex</other_name>
    <other_name>Folex PFS</other_name>
    <other_name>Lantarel</other_name>
    <other_name>Ledertrexate</other_name>
    <other_name>Lumexon</other_name>
    <other_name>Maxtrex</other_name>
    <other_name>Medsatrexate</other_name>
    <other_name>Metex</other_name>
    <other_name>Methoblastin</other_name>
    <other_name>Methotrexate LPF</other_name>
    <other_name>Methotrexate Methylaminopterin</other_name>
    <other_name>Methotrexatum</other_name>
    <other_name>Metotrexato</other_name>
    <other_name>Metrotex</other_name>
    <other_name>Mexate</other_name>
    <other_name>Mexate-AQ</other_name>
    <other_name>MTX</other_name>
    <other_name>Novatrex</other_name>
    <other_name>Rheumatrex</other_name>
    <other_name>Texate</other_name>
    <other_name>Tremetex</other_name>
    <other_name>Trexeron</other_name>
    <other_name>Trixilem</other_name>
    <other_name>WR-19039</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegfilgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (pembrolizumab, aMVAC)</arm_group_label>
    <other_name>Filgrastim SD-01</other_name>
    <other_name>filgrastim-SD/01</other_name>
    <other_name>Fulphila</other_name>
    <other_name>HSP-130</other_name>
    <other_name>Jinyouli</other_name>
    <other_name>Neulasta</other_name>
    <other_name>Neulastim</other_name>
    <other_name>Pegfilgrastim Biosimilar HSP-130</other_name>
    <other_name>Pegfilgrastim Biosimilar Pegcyte</other_name>
    <other_name>Pegfilgrastim-jmdb</other_name>
    <other_name>SD-01</other_name>
    <other_name>SD-01 sustained duration G-CSF</other_name>
    <other_name>Nyvepria</other_name>
    <other_name>Pegcyte</other_name>
    <other_name>Udenyca</other_name>
    <other_name>Ziextenzo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (pembrolizumab, aMVAC)</arm_group_label>
    <other_name>Keytruda</other_name>
    <other_name>Lambrolizumab</other_name>
    <other_name>MK-3475</other_name>
    <other_name>SCH 900475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical Cystectomy</intervention_name>
    <description>Undergo standard of care radical cystectomy</description>
    <arm_group_label>Treatment (pembrolizumab, aMVAC)</arm_group_label>
    <other_name>Complete Cystectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinblastine Sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (pembrolizumab, aMVAC)</arm_group_label>
    <other_name>29060 LE</other_name>
    <other_name>29060-LE</other_name>
    <other_name>Exal</other_name>
    <other_name>Velban</other_name>
    <other_name>Velbe</other_name>
    <other_name>Velsar</other_name>
    <other_name>VINCALEUKOBLASTINE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must have histologically confirmed diagnosis of muscle invasive bladder&#xD;
             cancer (cT2-T4a, N0-N1, M0 clinical stage per American Joint Commission on Cancer&#xD;
             [AJCC]). Clinical node-positive (N1) patients are eligible provided the lymph nodes&#xD;
             (LNs) are confined to the true pelvis and are within the planned surgical LN&#xD;
             dissection template&#xD;
&#xD;
          -  Histology must be either pure or predominant non-urothelial histology (noted on any&#xD;
             TURBT)&#xD;
&#xD;
          -  Participants must be deemed eligible for cisplatin-based chemotherapy, radical&#xD;
             cystectomy (RC) and pelvic lymph node dissection (PLND) by urologist and medical&#xD;
             oncologist&#xD;
&#xD;
          -  Patients must agree to undergo curative intent surgery&#xD;
&#xD;
          -  TURBT that showed muscularis propria invasion should be within 12 weeks prior to&#xD;
             beginning study therapy. Patients must have available tumor tissue from either initial&#xD;
             or repeat TURBT, prior to starting study therapy. Archival tumor tissue sample of a&#xD;
             tumor lesion (TURBT specimen) should be provided and must contain muscle invasive&#xD;
             component, at least &gt;= T2 tumor. Formalin-fixed, paraffin embedded (FFPE) tissue&#xD;
             blocks are preferred to slides. If submitting unstained cut slides, newly cut slides&#xD;
             should be submitted to the testing laboratory, preferably within 14 days from the date&#xD;
             slides are cut if possible. Patient must be willing to provide tumor tissue for&#xD;
             research. Research samples will not be used for any studies unrelated to this trial&#xD;
&#xD;
          -  Must have clinical non-metastatic bladder cancer (M0) determined by cross-sectional&#xD;
             computed tomography (CT) chest, abdomen and pelvis (CAP) or magnetic resonance imaging&#xD;
             (MRI) imaging&#xD;
&#xD;
          -  A male participant must agree to use a contraception during the treatment period and&#xD;
             for at least 180 days after the last dose of study treatment and refrain from donating&#xD;
             sperm during this period&#xD;
&#xD;
          -  A female participant is eligible to participate if she is not pregnant , not&#xD;
             breastfeeding, and at least one of the following conditions applies:&#xD;
&#xD;
               -  Not a woman of childbearing potential (WOCBP) OR&#xD;
&#xD;
               -  A WOCBP who agrees to follow the contraceptive guidance during the treatment&#xD;
                  period and for at least 180 days after the last dose of study treatment&#xD;
&#xD;
          -  The participant (or legally acceptable representative if applicable) provides written&#xD;
             informed consent for the trial&#xD;
&#xD;
          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.&#xD;
             Evaluation is to be performed within 7 days prior to the date of enrollment&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1500/uL (collected within 10 days prior to the&#xD;
             start of study treatment)&#xD;
&#xD;
          -  Platelets &gt;= 100 000/uL (collected within 10 days prior to the start of study&#xD;
             treatment)&#xD;
&#xD;
          -  Hemoglobin &gt;= 9.0 g/dL or &gt;= 5.6 mmol/L (collected within 10 days prior to the start&#xD;
             of study treatment)&#xD;
&#xD;
               -  Criteria must be met without erythropoietin dependency and without packed red&#xD;
                  blood cell (pRBC) transfusion within last 2 weeks&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 x upper limits of normal (ULN) OR calculated creatinine&#xD;
             clearance (glomerular filtration rate [GFR] can be used in place of creatinine or&#xD;
             creatinine clearance) &gt;= 50 ml/min (collected within 10 days prior to the start of&#xD;
             study treatment). Measured or calculated creatinine clearance (GFR can be used in&#xD;
             place of creatinine clearance; 24-hour urine collection can be used for more accurate&#xD;
             estimate as needed)&#xD;
&#xD;
               -  Creatinine clearance (CrCl) should be calculated per institutional standard&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x ULN OR direct bilirubin =&lt; ULN for participants with total&#xD;
             bilirubin levels &gt; 1.5 x ULN (collected within 10 days prior to the start of study&#xD;
             treatment)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and&#xD;
             alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =&lt; 2.5 x&#xD;
             ULN (collected within 10 days prior to the start of study treatment)&#xD;
&#xD;
          -  International normalized ratio (INR) OR prothrombin time (PT) =&lt; 1.5 x ULN unless&#xD;
             participant is receiving anticoagulant therapy, as long as PT is within therapeutic&#xD;
             range of intended use of anticoagulants (collected within 10 days prior to the start&#xD;
             of study treatment)&#xD;
&#xD;
          -  Activated partial thromboplastin time (aPTT) =&lt; 1.5 x ULN unless participant is&#xD;
             receiving anticoagulant therapy, as long as aPTT is within therapeutic range of&#xD;
             intended use of anticoagulants (collected within 10 days prior to the start of study&#xD;
             treatment)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A WOCBP who has a positive urine pregnancy test within 72 hours prior to enrollment.&#xD;
             If the urine test is positive or cannot be confirmed as negative, a serum pregnancy&#xD;
             test will be required&#xD;
&#xD;
          -  Patients with pure small cell histology will be excluded. Mixed histology including&#xD;
             partial neuroendocrine small cell features will be permitted&#xD;
&#xD;
          -  Patients considered to be medically unfit for accelerated (dose dense) MVAC&#xD;
             chemotherapy, TURBT or RC (per investigator discretion) will be excluded&#xD;
&#xD;
          -  Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with&#xD;
             an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g.,&#xD;
             CTLA-4, OX 40, CD137)&#xD;
&#xD;
          -  Has received prior systemic anti-cancer therapy including investigational agents&#xD;
             within 4 weeks. Intravesical therapies are allowed without specified treatment&#xD;
             interval&#xD;
&#xD;
               -  Note: Participants must have recovered from all adverse events (AEs) due to&#xD;
                  previous therapies to =&lt; grade 1 or baseline. If participant had major surgery,&#xD;
                  they must have recovered adequately from the toxicity and/or complications from&#xD;
                  the intervention prior to starting study treatment&#xD;
&#xD;
          -  Has received prior radiotherapy within 2 weeks of start of study treatment.&#xD;
             Participants must have recovered from all radiation-related toxicities, not require&#xD;
             corticosteroids, and should not have active radiation pneumonitis&#xD;
&#xD;
          -  Has received a live vaccine within 30 days prior to the first dose of study drug.&#xD;
             Examples of live vaccines include, but are not limited to, the following: measles,&#xD;
             mumps, rubella, a version of varicella/zoster (chicken pox), yellow fever, rabies,&#xD;
             Bacillus calmette-guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for&#xD;
             injection are generally killed virus vaccines and are allowed; however, intranasal&#xD;
             influenza vaccines (eg, FluMist) are live attenuated vaccines and are not allowed&#xD;
&#xD;
          -  Is currently participating in or has participated in a study of an investigational&#xD;
             agent or has used an investigational device within 4 weeks prior to the first dose of&#xD;
             study treatment&#xD;
&#xD;
               -  Note: Participants who have entered the follow-up phase of an investigational&#xD;
                  study may participate as long as it has been 4 weeks after the last dose of the&#xD;
                  previous investigational agent&#xD;
&#xD;
          -  Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in&#xD;
             dosing &gt; 10 mg daily of prednisone dose equivalent) or any other form of&#xD;
             immunosuppressive therapy within 7 days prior to the first dose of study drug&#xD;
&#xD;
          -  Has known additional malignancy that is progressing or has required active systemic&#xD;
             treatment within the past 2 years. Note: Participants with basal cell carcinoma or&#xD;
             squamous cell carcinoma of the skin, or any carcinoma in situ that have undergone&#xD;
             potentially curative therapy are not excluded. Low/intermediate risk prostate cancer&#xD;
             with prior potentially curative therapy, or no intent of future systemic therapy&#xD;
             and/or radiation is allowed. Non-invasive (Tis, Ta) upper urinary tract (renal&#xD;
             pelvis/ureter) is allowed. Urethra cancer with prior curative intent therapy with no&#xD;
             active recurrence is also allowed regardless of time elapsed&#xD;
&#xD;
          -  Has known locally advanced (unresectable) or metastatic cancer on baseline&#xD;
             radiographic imaging (CT or MRI) obtained within 28 days prior to study registration&#xD;
&#xD;
          -  Has severe hypersensitivity (&gt;= grade 3) to pembrolizumab and/or any of its excipients&#xD;
&#xD;
          -  Has active autoimmune disease that has required systemic treatment in the past 2 years&#xD;
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a&#xD;
             form of systemic treatment and is allowed. Note: Patients with active well controlled&#xD;
             type 1 diabetes mellitus, vitiligo, Graves' disease, Hashimoto disease, eczema, lichen&#xD;
             simplex chronicus, or psoriasis, not requiring systemic immunosuppression within the&#xD;
             past 2 years are not excluded&#xD;
&#xD;
          -  Has history of (non-infectious) pneumonitis that required steroids or has current&#xD;
             pneumonitis&#xD;
&#xD;
          -  Has an active infection requiring systemic therapy&#xD;
&#xD;
          -  Has known history of human immunodeficiency virus (HIV). Note: no HIV testing is&#xD;
             required&#xD;
&#xD;
          -  Has known history of active hepatitis B (defined as hepatitis B surface antigen&#xD;
             [HBsAg] detected) or known active hepatitis C virus (defined as hepatitis C virus&#xD;
             [HCV] ribonucleic acid [RNA] [qualitative] detected) infection. Note: no testing for&#xD;
             hepatitis B and hepatitis C is required&#xD;
&#xD;
          -  Has known history of active TB (Bacillus tuberculosis). Note: no testing is required&#xD;
             unless it is clinically indicated&#xD;
&#xD;
          -  Has history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the study, interfere with the subject's&#xD;
             participation for the full duration of the study, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating investigator&#xD;
&#xD;
          -  Has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial&#xD;
&#xD;
          -  Has had allogeneic solid visceral organ transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petros Grivas</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Petros Grivas</last_name>
    <phone>206.606.1821</phone>
    <email>pgrivas@uw.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petros Grivas</last_name>
      <phone>206-606-1821</phone>
      <email>pgrivas@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Petros Grivas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 7, 2020</study_first_submitted>
  <study_first_submitted_qc>May 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

